Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Sun Pharma

Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.

The Economic Times

Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the…

The Economic Times

Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap plays

Indian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries is highlighted as a strong recovery story, while Nykaa and Honasa are viewed cautiously. The pharma sector continues its outperformance, with Sun Pharma and Aurobindo Pharma looking attractive.

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks in news: ITC, LIC, Sun Pharma, Maruti Suzuki, Fino Payments Bank

Benchmark indices experienced a negative close on Thursday, marked by volatile trade and profit booking. Analysts anticipate the Nifty to continue its consolidation between 23,200 and 23,900. Several companies, including ITC, LIC, Sun Pharma, Maruti Suzuki, and Fino Payments Bank, are in focus due to Q4 results and other developments.

The Economic Times

Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?

Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages highlight US portfolio strength, new launches like Unloxcyt, and a steady margin outlook despite higher R&D spending, with EBITDA growth supported by diversified global business momentum…

The Economic Times

Jio Financial, ITC Hotels and Manappuram Finance among stocks bought and sold by mutual funds in April

Mutual funds injected Rs 30,600 crore into Indian equities in April, with significant buying in ICICI Bank, SBI, and Sun Pharma. Key reductions were observed in Wipro, HDFC Bank, and Hindalco Industries across large, mid, and smallcap segments. This active portfolio management reflects ongoing strategic shifts by fund managers.

The Economic Times

When the world's an oyster for Sun (Pharma)

Indian companies are increasingly making bold acquisitions abroad. Sun Pharma's deal signals a new era of deliberate empire-building. This shift from tentative deals to strategic bets is crucial for global relevance. Successful acquisitions require clear intent, respect for acquired assets, integration discipline, financial courage, and a long-term mindset.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

7 Things That Will Get Cheaper After Budget 2026

Most budgets promise relief. Very few actually change what you pay in real life. Budget 2026 is one of those rare ones that works quietly. There were no dramatic tax cuts, no loud announcements, and no instant price drops flashed across screens. Yet, beneath the fine print, the government made…

Times Life

FDA let risky drugs into US

The FDA let risky drugs from banned foreign plants into the United States

Salon

Quality lapse by major pharma firms in India, 53 drugs and leading companies under scrutiny

India's drug regulator, the Central Drugs Standards Control Organisation (CDSCO), has listed more than 50 drugs as "Not of Standard Quality (NSQ) Alert" in its latest monthly report. This list includes widely used medicines such as calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines.

The Times of India

Interpol candidate accused of role in kidnap of Indian businessmen

Zambia’s Mubita Nawa, who is on shortlist for top job, is accused of involvement in an attempted extortion in 2022

The Guardian - UK

Sun Pharma says it relied on Google Maps to show company lies outside Vedanthangal bird sanctuary limits

Sun Pharmaceuticals has informed the southern bench of the National Green Tribunal (NGT) that it relied on Google Maps to submit the location of its manufacturing plant in Sathamai in the pre-feasibility report submitted as part of the environmental clearance application

The Hindu

Drug giant Sun Pharma warned over manufacturing violations. What does this mean for Australia?

Questions have been raised about how Australia ensures the quality of its imported medicines after a major pharmaceutical company was warned over lapses in contamination control and manufacturing practices.

ABC News

What is the MSCI India Index and why it matters

NEW DELHI: Global indices service provider MSCI had earlier this month announced a couple of inclusion and exclusion, along with changes in weightages of a few Indian stocks, which has influenced flows in these stocks. While it has added four stocks to its MSCI India index, namely Tata Elxsi, Adani…

The Times of India

Get all your
news in one place.

100's of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.